Company Valuation: GlaxoSmithKline Pharmaceuticals Limited

Data adjusted to current consolidation scope
Fiscal Period: March 2022 2023 2024 2025 2026 2027 2028
Market Cap 1 281,714 224,319 329,173 487,432 386,822 407,066 -
Change - -20.37% 46.74% 48.08% -20.64% 5.23% -
Enterprise Value (EV) 256,351 207,663 329,173 487,432 386,822 407,066 407,066
Change - -18.99% 58.51% 48.08% -20.64% 5.23% 0%
P/E 16.6x 36.7x 55.8x 52.5x 37.3x 35.3x 31.1x
PBR 10.6x 12.9x 18.5x 25x 17.1x 15.3x 13x
PEG - -0.6x -16.49x 0.9x 3.2x 3.2x 2.3x
Capitalization / Revenue 8.59x 6.9x 9.53x 13x 10.1x 9.71x 8.76x
EV / Revenue 0x 0x 0x 0x 0x 9.71x 8.76x
EV / EBITDA 0x 0x 0x 0x 0x 27.7x 24.4x
EV / EBIT 0x 0x 0x 0x 0x 29.6x 25.9x
EV / FCF 0x 0x 0x 0x 0x 35.1x 31.7x
FCF Yield 2.75% 1.96% 1.67% 2.6% 2.19% 2.85% 3.16%
Dividend per Share 2 30 32 32 42 57 29.5 29.5
Rate of return 1.8% 2.42% 1.65% 1.46% 2.5% 1.23% 1.23%
EPS 2 100 36.05 34.83 54.76 61.15 67.98 77.28
Distribution rate 30% 88.8% 91.9% 76.7% 93.2% 43.4% 38.2%
Net sales 1 32,780 32,517 34,537 37,492 38,217 41,939 46,453
EBITDA 1 8,273 8,043 9,087 11,774 13,092 14,683 16,675
EBIT 1 7,592 7,385 8,390 11,106 12,428 13,760 15,728
Net income 1 16,947 6,107 5,900 9,276 10,360 11,515 12,873
Net Debt -25,363 -16,656 - - - - -
Reference price 2 1,662.95 1,324.15 1,943.10 2,877.30 2,283.40 2,402.90 2,402.90
Nbr of stocks (in thousands) 169,406 169,406 169,406 169,406 169,406 169,406 -
Announcement Date 5/16/22 5/17/23 5/17/24 5/13/25 5/13/26 - -
1INR in Million2INR
Estimates

P/E, Detailed evolution

P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
35.67x - - 1.23% 4.26B
35.08x12.75x25.97x0.57% 1,070B
27.67x6.37x17.29x2.06% 624B
31.08x7.52x15.39x2.69% 450B
17.65x4.4x10.87x3.02% 328B
21.61x5.56x13.43x2.84% 284B
14.17x5.28x10.84x3.53% 217B
23.97x6.34x11.16x2.75% 198B
-45.95x5.59x31.09x2.5% 161B
11.55x2.99x7.34x7.38% 135B
Average 17.25x 6.31x 15.93x 2.86% 347.17B
Weighted average by Cap. 23.87x 8.00x 18.30x 2.19%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

Year-on-year evolution of the Yield

  1. Stock Market
  2. Stocks
  3. GLAXO Stock
  4. Valuation GlaxoSmithKline Pharmaceuticals Limited